Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Trials
Published in: Trials 1/2019

Open Access 01-12-2019 | Addiction | Research

A randomized clinical trial on the effects of bupropion and buprenorphine on the reduction of methamphetamine craving

Authors: Jamshid Ahmadi, Ali Sahraian, Mehdi Biuseh

Published in: Trials | Issue 1/2019

Login to get access

Abstract

Background

The purpose of this study was to compare the effect of 300 mg of bupropion and 8 mg of buprenorphine per day on the treatment of methamphetamine withdrawal cravings over a 2-week treatment interval.

Method

Sixty-five methamphetamine-dependent men who met the DSM-IV-TR (Diagnostic and Statistical Manual of Mental Disorders, 4th edition, text revision) criteria for methamphetamine dependence and withdrawal were randomly divided into two groups. Subjects randomly received 300 mg of bupropion or 8 mg of buprenorphine per day in a psychiatric ward. Of the 65 subjects, 35 (53.8%) received buprenorphine and 30 (46.2%) received bupropion. The subjects were assessed by using methamphetamine craving score, interview, and negative urine drug test.

Findings

There were no statistically significant differences between the two groups in regard to age, education, duration of methamphetamine dependency, marital status, employment, and income. The mean ages were 32.8 years (standard deviation (SD) = 7.26, range = 22 to 59) for the buprenorphine group and 32.21 years (SD = 8.45, range = 17 to 51) for the bupropion group. All 65 patients completed the 2-week study. Both medications were effective in the reduction of methamphetamine cravings. Reduction of craving in the buprenorphine group was significantly more than the bupropion group (P = 0.011). Overall, a significant main effect of day (P <0.001) and group (P = 0.011) and a non-significant group-by-day interaction (P >0.05) were detected.

Conclusions

The results support the safety and effectiveness of buprenorphine and bupropion in the treatment of methamphetamine withdrawal craving. Administration of 8 mg of buprenorphine per day can be recommended for the treatment of methamphetamine withdrawal cravings. We should note that it is to be expected that craving decreases over time without any medication. So the conclusion may not be that bupropion and buprenorphine both lower the craving. As the buprenorphine is superior to bupropion, only buprenorphine does so for sure.

Trial registration

Iranian Registry of Clinical Trials (IRCT) registration number: IRCT201501032054​0N1. Date registered: April 10, 2015.
Literature
1.
Ahmadi J, Ahmadi N, Soltani F, Bayat F. Gender differences in depression scores of Iranian and German medical students. Iran J Psychiatry Behav Sci. 2014;8:70–3.PubMedPubMedCentral
2.
Mackay-Smith M, Ahmadi J, Pridmore S. Suicide in shooting galleries. ASEAN J Psychiatry. 2015;16:50–6.
3.
Ahmadi J, Fakoor A, Pezeshkian P, Khoshnood R, Malekpour A. Substance use among Iranian psychiatric inpatients. Psychol Rep. 2001;89:363–5.CrossRef
4.
5.
Ahmadi J, Kampman K, Osline DM, Pettinati HM, Dackis C, Sparkman T. Predictors of treatment outcome in outpatient cocaine and alcohol dependence treatment. Am J Addict. 2009;18:81–6.CrossRef
6.
Ahmadi J, Kampman K, Dackis C, Sparkman T, Pettinati H. Cocaine withdrawal symptoms identify type B cocaine-dependent patients. Am J Addict. 2008;17:60–4.CrossRef
7.
Sadock B, Sadock V, Ruiz P, editors. Kaplan and Sadock’s Synopsis of Psychiatry: Substance Use and Addictive Disorders. Chapter 20 ed. Philadelphia: Lippincott Williams and Wilkins; 2015. p. 616–93.
8.
Ahmadi J, Keshtkar M, Pridmore S. Methamphetamine induced synesthesia: a case report. Am J Addict. 2011;20:306.CrossRef
9.
10.
Ahmadi J. The effect of buprenorphine and bupropion in the treatment of methamphetamine dependency and craving. Br J Med Med Res. 2015;10:1–4.CrossRef
11.
Ahmadi J, Sefidfard M. Anxiety treatment of opioid dependent patients with buprenorphine: A randomized, double-blind, clinical trial. Indian J Psychol Med. 2017;39:445–9.CrossRef
12.
Hoffman WF, Moore M, Templin R, McFarland B, Hitzemann RJ, Mitchell SH. Neuropsychological function and delay discounting in methamphetamine-dependent individuals. Psychopharmacology. 2006;188:162–70.CrossRef
13.
Salo R, Nordahl TE, Natsuaki Y, Leamon MH, Galloway GP, Waters C, et al. Attentional control and brain metabolite levels in methamphetamine abusers. Biol Psychiatry. 2007;61:1272–80.CrossRef
14.
Ahmadi J. Methylphenidate in the treatment of methamphetamine withdrawal craving: a novel outcome. J Drug Abuse. 2016;2:12.CrossRef
15.
16.
Ahmadi J. Recurrent psychosis related to methamphetamine. J Harmoniz Res Med and HlthSci. 2016;3:51–5.
17.
Lovinger DM, Roberto M. Synaptic effects induced by alcohol. Curr Top Behav Neurosci. 2013;13:31–86.CrossRef
18.
Ray LA, Chin PF, Miotto K. Naltrexone for the treatment of alcoholism: clinical findings, mechanisms of action, and pharmacogenetics. CNS Neurol Disord Drug Targets. 2010;9:13–22.CrossRef
19.
Manglik A, Kruse AC, Kobilka TS, Thian FS, Mathiesen JM, Sunahara RK, et al. Crystal structure of the micro-opioid receptor bound to a morphinan antagonist. Nature. 2012;485:321–6.CrossRef
20.
Huang W, Manglik A, Venkatakrishnan AJ, Laeremans T, Feinberg EN, Sanborn AL, et al. Structural insights into micro-opioid receptor activation. Nature. 2015;524:315–21.CrossRef
21.
Kaserer T, Lantero A, Schmidhammer H, Spetea M, Schuster D. Mu opioid receptor: novel antagonists and structural modeling. Sci Rep. 2016;6:21548.CrossRef
22.
Moratti E, Kashanpour H, Lombardelli T, Maisto M. Intravenous misuse of buprenorphine: characteristics and extent among patients undergoing drug maintenance therapy. Clin Drug Investig. 2010;30(suppl 1):3–11.CrossRef
23.
Uosukainen H, Pentikäinen H, Tacke U. The effect of an electronic medicine dispenser on diversion of buprenorphine naloxone experience from a medium-sized Finnish city. J Subst Abus Treat. 2013;45:143–7.CrossRef
24.
Pasternak GW. Opiate pharmacology and relief of pain. J Clin Oncol. 2014;32:1637–9.CrossRef
25.
Spetea M, Asim MF, Wolber G, Schmidhammer H. The μ opioid receptor and ligands acting at the μ opioid receptor, as therapeutics and potential therapeutics. Curr Pharm Des. 2013;19:7415–34.CrossRef
26.
Lofwall MR, Havens JR. Inability to access buprenorphine treatment as a risk factor for using diverted buprenorphine. Drug Alcohol Depend. 2012;126:379–83.CrossRef
27.
Cicero TJ, Ellis MS, Surratt HL, Kurtz SP. Factors contributing to the rise of buprenorphine misuse: 2008–2013. Drug Alcohol Depend. 2014;142:98–104.CrossRef
28.
Clark RE, Baxter JD. Responses of state Medicaid programs to buprenorphine diversion: doing more harm than good? JAMA Intern Med. 2013;173:1571–2.CrossRef
29.
Lofwall MR, Wunsch MJ, Nuzzo PA, Walsh SL. Efficacy of continuing medical education to reduce the risk of buprenorphine diversion. J Subst Abuse Treat. 2011;41:321–9.CrossRef
30.
Yang A, Arfken CL, Johanson CE. Steps physicians report taking to reduce diversion of buprenorphine. Am J Addict. 2013;22:184–7.CrossRef
31.
Arfken CL, Johanson CE, Di Menza S, Schuster CR. Expanding treatment capacity for opioid dependence with office-based treatment with buprenorphine: national survey of physicians. J Subst Abus Treat. 2010;39:96–104.CrossRef
32.
Lofwall MR, Wunsch MJ, Walsh SL. Pharmacy willingness to partner with office-based opioid dependence treatment providers in conducting random buprenorphine pill counts. Am J Addict. 2010;19:195–6.CrossRef
33.
Knudsen HK. The supply of physicians waivered to prescribe buprenorphine for opioid use disorders in the United States: a state-level analysis. J Stud Alcohol Drugs. 2015;76:644–54.CrossRef
Metadata
Title
A randomized clinical trial on the effects of bupropion and buprenorphine on the reduction of methamphetamine craving
Authors
Jamshid Ahmadi
Ali Sahraian
Mehdi Biuseh
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Trials / Issue 1/2019
Electronic ISSN: 1745-6215
DOI
https://doi.org/10.1186/s13063-019-3554-6

Other articles of this Issue 1/2019

Trials 1/2019 Go to the issue

Study protocol

Critical inspiratory pressure – a new methodology for evaluating and training the inspiratory musculature for recreational cyclists: study protocol for a randomized controlled trial

Study protocol

The effect of a heel-unloading orthosis in short-term treatment of calcaneus fractures on physical function, quality of life and return to work – study protocol for a randomized controlled trial

Study protocol

Use of a smartphone app combined with gamification to increase the level of physical activity of adults and older adults: protocol of a sequential multiple assignment randomized trial

Study protocol

Electronic health record nested pragmatic randomized controlled trial of a reminder system for serum lithium level monitoring in patients with mood disorder: KONOTORI study protocol

Methodology

Involving people living with dementia in research: an accessible modified Delphi survey for core outcome set development

Study protocol

Enteral Nutrition Tolerance And REspiratory Support (ENTARES) Study in preterm infants: study protocol for a randomized controlled trial